Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Nivolumab further demonstrates increase in overall survival in NSCLC

Bristol-Myers Squibb today announced results from the pooled analysis of two studies (CheckMate -017 and -057) of 5 year overall survival (OS) in patients with previously-treated advanced non-small cell lung cancer (NSCLC).

At five years, patients who were treated with nivolumab experienced a five-fold increase in long-term OS benefit versus docetaxel, with OS rates of 13.4% versus 2.6%, respectively.

The primary endpoint of OS benefit (CheckMate 017 mOS 9.2 vs 6.0 months, HR 0.59, 95% CI 0.4, 0.79; p<0.001; CheckMate 057 mOS 12.2 vs 9.4 months, HR 0.73, 96% CI 0.59, 0.89; p=0.002) for nivolumab-treated patients was observed across all subgroups.

The safety profile for patients treated with nivolumab was consistent with previously reported findings in second-line NSCLC and no new safety signals were seen with extended follow-up.

Of patients still on study, only two of 70 (1.4%) experienced a new treatment-related select adverse event (AE) between years three and four and there were no new treatment-related select AEs reported between years four and five among the 55 patients still on the study.

Among patients with an objective response to nivolumab, 32.2% continued to see a response at five years compared to 0% on docetaxel.

The median duration of response was 19.9 months for nivolumab-treated patients versus 5.6 months for docetaxel.

Lung cancer is the most common cause of cancer death in the UK and accounts for 21% of all cancer deaths.

NSCLC accounts for nearly 90% of all lung cancer cases.

There are around 47,200 new lung cancer cases diagnosed in the UK every year and around three-quarters of lung cancer cases are diagnosed at a late stage (where the cancer has spread to other parts of the body) in England.

“We are delighted with the results of the pooled analysis, which demonstrate the long-term survival outcomes, in a large patient population, and provides evidence of the five year durability of nivolumab,”said Faisal Mehmud, UK Country Medical Director, Bristol-Myers Squibb.

“IO has become an important treatment option for patients living with NSCLC and these data help to reinforce the place of nivolumab in the treatment pathway.”

Source: Bristol-Myers Squibb



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation